. Indian Journal Med Res 2004; 120(4): 354-76.
Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis
. Eur Respir J.
: treatment and outcomes of 93 patients.
is immune to two of the most common antibacterial drugs used to treat the disease.
Risk factors for multidrug-resistant tuberculosis
in Diyarbakir, Turkey.
: epidemiology, risk factors and case finding.
Impact of diabetes on treatment outcomes and long-term survival in multidrug-resistant tuberculosis
. Respiration 2013;86(6):472-8.
This finding is lower as compared to the 2017 WHO anti-TB drug resistance surveillance data report, which showed that 4.1% of new and 19% of previously treated TB cases in the world are estimated to have Rifampicin-resistant or multidrug-resistant tuberculosis
The World Health Organization (WHO) estimates that, globally in 2016, there were around 600,000 incident cases of rifampicin-resistant tuberculosis (TB) of which 490,000 had multidrug-resistant tuberculosis
(MDR-TB) with India, China, and Russian federation accounting for almost 47% of these cases .
Global incidence of multidrug-resistant tuberculosis
. J Infect Dis 2006; 194(4): 479-85.
In addition to multidrug-resistant tuberculosis
, WHO has identified 12 classes of priority pathogens - some of them causing common infections such as pneumonia or urinary tract infections - that are increasingly resistant to existing antibiotics and urgently in need of new treatments.
of the ankle: Case report.